Commodore Capital is invested in the early stages of a major innovation cycle in biopharmaceuticals.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Commodore Capital is invested in the early stages of a major innovation cycle in biopharmaceuticals.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
6/2020 | C4 Therapeutics | Series B | 150M |
9/2022 | Allakos | Post-IPO Equity | 0 |
1/2022 | Third Harmonic Bio | Series B | 0 |
6/2020 | Mereo Biopharma | Post-IPO Equity | 0 |
7/2021 | Nimbus Therapeutics | Private Equity Round | 105M |
7/2022 | Arkive | Seed Round | 0 |
2/2021 | Shoreline Biosciences | Series A | 0 |
10/2022 | Immunovant | Post-IPO Equity | 75M |
8/2020 | Kronos Bio | Private Equity Round | 155M |
5/2022 | Celcuity | Post-IPO Equity | 0 |
11/2021 | Shoreline Biosciences | Series B | 0 |
2/2023 | Abivax | Post-IPO Equity | 0 |
10/2022 | Immunic Therapeutics | Post-IPO Equity | 60M |
7/2020 | Cogent Biosciences | Post-IPO Equity | 104.4M |
3/2021 | Satsuma Pharmaceuticals | Post-IPO Equity | 0 |
7/2022 | Arkive | Seed Round | 0 |
5/2022 | Celcuity | Post-IPO Equity | 0 |
1/2022 | Third Harmonic Bio | Series B | 0 |
11/2021 | Shoreline Biosciences | Series B | 0 |
7/2021 | Nimbus Therapeutics | Venture Round | 0 |
3/2021 | Satsuma Pharmaceuticals | Post-IPO Equity | 0 |
2/2021 | Shoreline Biosciences | Series A | 0 |
8/2020 | Kronos Bio | Private Equity Round | 0 |
7/2020 | Cogent Biosciences | Post-IPO Equity | 0 |
6/2020 | C4 Therapeutics | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|